Applicable population of ischemia modified albumin assay kit

The applicable population of the ischemia modified albumin (IMA) assay kit is mainly suspected acute myocardial ischemia or chest pain patients. The specific analysis is as follows:

1. Core applicable population

Suspected acute myocardial ischemia patients

IMA is a sensitive biochemical marker of early myocardial ischemia, which can increase within minutes after myocardial cell ischemia and hypoxia, earlier than traditional myocardial injury markers (such as troponin and creatine kinase isoenzyme).

Suitable for emergency departments, cardiology, chest pain centers and other scenarios, it can assist in the diagnosis of acute coronary syndrome (ACS), shorten the diagnosis time window, and provide a basis for clinical intervention.

.

Chest pain patients

By rapidly measuring IMA concentration, combined with other clinical information and examination results, it can effectively assist in the differential diagnosis of non cardiogenic chest pain and optimize the allocation of medical resources.

.

II. Other applicable scenarios

Screening of high-risk groups of cardiovascular disease

IMA test can be used to assess the risk of myocardial ischemia in people with high-risk factors of coronary heart disease such as hypertension, hyperlipidemia, diabetes, smoking, etc.

Evaluation of therapeutic effect

In the treatment of some cardiovascular diseases, changes in IMA concentration can reflect the improvement of myocardial ischemia and assist in evaluating the therapeutic effect.

.

III. Not applicable

Non myocardial ischemia related diseases

IMA cannot be used as the sole basis for early identification or diagnosis of acute myocardial infarction, and should be combined with other biomarkers (such as troponin) and clinical manifestations for comprehensive judgment.

. The value of IMA detection is limited for chest pain caused by non myocardial ischemia (such as pulmonary embolism, pneumothorax, etc.). The IMA concentration in special populations such as pregnant women and patients with severe liver and kidney dysfunction may be influenced by other factors, and the results should be interpreted with caution.

IV. Detection Characteristics and Advantages

Rapid: IMA can increase within minutes after myocardial ischemia, making it suitable for rapid screening in emergency settings.

. Sensitivity: The detection sensitivity for early myocardial ischemia is higher than that of traditional biomarkers. Specificity: The kit is designed for human IMA to ensure specific recognition and response. Sample type: Mainly used to detect serum or plasma separated from human venous blood, easy to operate.